New eye drops aim to soothe dry eye sufferers

NCT ID NCT04343287

Completed Symptom relief Sponsor: BRIM Biotechnology Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether BRM421 eye drops can safely reduce the signs and symptoms of dry eye compared to a placebo. 220 adults with dry eye for at least 6 months received either the active drops or a placebo. The main outcomes were changes in corneal staining (eye surface damage) and patient-reported dryness after 14 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BRM421 ophthalmic solution (eye drops)
What this could lead to: If successful, BRM421 could offer a new treatment option to reduce eye damage and dryness in people with dry eye syndrome.
What could go wrong: This is an early-to-mid stage trial with only 220 participants. The results may not show a meaningful benefit over placebo, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE SYNDROME

Contacts and locations

Locations

Andover Eye Associates

Andover, Massachusetts, 01810, United States
Eye Research Foundation

Newport Beach, California, 92663, United States
Midwest Cornea Associates, LLC

Indianapolis, Indiana, 46290, United States
Total Eye Care

Memphis, Tennessee, 38119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.